Key facts
- Laurus Bio’s last known valuation is $46.3M (Jan 2021).
- It has raised $14.2M; the latest was Later Stage VC ($14.2M) in Dec 2024.
- Notable investors include F-Prime Capital, Eight Roads, Unreasonable Impact.
- Status: Acquired/Merged (Operating Subsidiary).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Laurus Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Laurus Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Laurus Bio
Developer of novel enzymatic proteins designed to serve the pharmaceutical, meat, and biomanufacturing industries. The company develops novel non-animal origin recombinant proteins, including media components, reagents, excipients, and drug products that enhance safety, consistency, traceability, and competitiveness for the medical industries, enabling clients to make greener, cleaner, and sustainable products for healthcare.
- Sector
- Healthcare
- HQ
- Bangalore, India
- Founded
- 2005
- Employees
- 459
- Website
- laurus.bio/
- Ownership
- Acquired/Merged (Operating Subsidiary)
Laurus Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Laurus Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Laurus Bio in its N-PORT filings yet. We sweep new filings monthly.